Cart
sales@molnova.com
PROTAC ERRα ligand 2
CAS No. 2306388-57-6
PROTAC ERRα ligand 2( —— )
Catalog No. M20565 CAS No. 2306388-57-6
PROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist( IC50 : 5.67 nM)
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 79 | In Stock |
|
| 5MG | 132 | In Stock |
|
| 10MG | 177 | In Stock |
|
| 25MG | 356 | In Stock |
|
| 50MG | 537 | In Stock |
|
| 100MG | 767 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePROTAC ERRα ligand 2
-
NoteResearch use only, not for human use.
-
Brief DescriptionPROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist( IC50 : 5.67 nM)
-
DescriptionPROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist( IC50 : 5.67 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorERRα
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2306388-57-6
-
Formula Weight445.31
-
Molecular FormulaC20H13F6NO4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (140.35 mM)
-
SMILESCOc1cc(\C=C(/C#N)C(O)=O)ccc1OCc1ccc(cc1C(F)(F)F)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Peng L Zhang Z Lei C et al. Identification of New Small-Molecule Inducers of Estrogen-Related Receptor alpha (ERRa) Degradation[J]. ACS Medicinal Chemistry Letters 2019 10(5).
molnova catalog
related products
-
Zindoxifene
Zindoxifene (D 16726) is an anti-estrogenic compound with antitumor activity that can be used in studies of breast and prostate cancer.
-
Allylestrenol
Allylestrenol is a synthetic steroid with progestational activity.
-
GDC-0927
GDC-0927 (SRN-927, RG-6047) is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) for treatment of metastatic hormone receptor-positive/HER2-negative breast cancer.
